LARIMAR THERAPEUTICS, INC. Cash and Cash Equivalents, Period Increase (Decrease)
LARIMAR THERAPEUTICS, INC. (LRMR) reported Cash and Cash Equivalents, Period Increase (Decrease) of $8.55 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-14.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-03-14
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $4.19M, a 80.59% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was $4.40M.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was -$4.99M, a 261.15% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2018-03-31 was $4.95M.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2018 was $8.55M, a 1.53% increase from fiscal 2017.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $8.43M.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.24M.
- LARIMAR THERAPEUTICS, INC. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$22.51M, a 199.65% decline from fiscal 2014.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2018-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $8.59M derived: sum of 2 quarters · filed 2019-03-14 | $3.60M derived: sum of 3 quarters · filed 2019-03-14 | $8.55M 10-K · filed 2019-03-14 |
| 2018-09-30 | $4.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$590.00K derived: sum of 2 quarters · filed 2018-11-09 | $4.36M 10-Q · filed 2018-11-09 | $25.95M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-06-30 | -$4.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$32.00K 10-Q · filed 2018-08-09 | $21.55M derived: sum of 3 quarters · filed 2019-03-14 | $9.02M derived: sum of 4 quarters · filed 2019-03-14 |
| 2018-03-31 | $4.95M 10-Q · filed 2018-05-10 | $26.54M derived: sum of 2 quarters · filed 2019-03-14 | $14.01M derived: sum of 3 quarters · filed 2019-03-14 | $17.10M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-12-31 | $21.58M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $9.05M derived: sum of 2 quarters · filed 2019-03-14 | $12.14M derived: sum of 3 quarters · filed 2019-03-14 | $8.43M 10-K · filed 2019-03-14 |
| 2017-09-30 | -$12.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | -$9.44M derived: sum of 2 quarters · filed 2018-11-09 | -$13.16M 10-Q · filed 2018-11-09 | -$5.67M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-06-30 | $3.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$626.00K 10-Q · filed 2018-08-09 | $6.87M derived: sum of 3 quarters · filed 2019-03-14 | $11.70M derived: sum of 4 quarters · filed 2019-03-14 |
| 2017-03-31 | -$3.72M 10-Q · filed 2018-05-10 | $3.77M derived: sum of 2 quarters · filed 2019-03-14 | $8.61M derived: sum of 3 quarters · filed 2019-03-14 | -$2.82M derived: sum of 4 quarters · filed 2019-03-14 |
| 2016-12-31 | $7.49M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $12.33M derived: sum of 2 quarters · filed 2019-03-14 | $902.00K derived: sum of 3 quarters · filed 2019-03-14 | -$3.24M 10-K · filed 2019-03-14 |
| 2016-09-30 | $4.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$6.59M derived: sum of 2 quarters · filed 2017-11-07 | -$10.73M 10-Q · filed 2017-11-07 | -$13.90M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-06-30 | -$11.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | -$15.57M 10-Q · filed 2017-08-09 | -$18.74M derived: sum of 3 quarters · filed 2018-03-09 | -$63.55M derived: sum of 4 quarters · filed 2018-03-09 |
| 2016-03-31 | -$4.14M 10-Q · filed 2017-05-09 | -$7.31M derived: sum of 2 quarters · filed 2018-03-09 | -$52.12M derived: sum of 3 quarters · filed 2018-03-09 | -$75.48M derived: sum of 4 quarters · filed 2018-03-09 |
| 2015-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$47.98M derived: sum of 2 quarters · filed 2018-03-09 | -$71.34M derived: sum of 3 quarters · filed 2018-03-09 | -$22.51M 10-K · filed 2018-03-09 |
| 2015-09-30 | -$44.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$68.17M derived: sum of 2 quarters · filed 2016-11-09 | -$19.34M 10-Q · filed 2016-11-09 | -$88.27M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-06-30 | -$23.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $25.47M 10-Q · filed 2016-08-05 | -$43.46M derived: sum of 3 quarters · filed 2017-03-10 | -$50.66M derived: sum of 4 quarters · filed 2017-03-10 |
| 2015-03-31 | $48.83M 10-Q · filed 2016-05-10 | -$20.10M derived: sum of 2 quarters · filed 2017-03-10 | -$27.30M derived: sum of 3 quarters · filed 2017-03-10 | $68.45M derived: sum of 4 quarters · filed 2017-03-10 |
| 2014-12-31 | -$68.93M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10 | -$76.13M derived: sum of 2 quarters · filed 2017-03-10 | $19.62M derived: sum of 3 quarters · filed 2017-03-10 | $22.59M 10-K · filed 2017-03-10 |
| 2014-09-30 | -$7.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $88.55M derived: sum of 2 quarters · filed 2015-11-13 | $91.51M 10-Q · filed 2015-11-13 | $122.19M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-06-30 | $95.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-14 | $98.72M 10-Q · filed 2015-08-14 | $129.39M derived: sum of 3 quarters · filed 2016-03-15 | $125.78M derived: sum of 4 quarters · filed 2016-03-15 |
| 2014-03-31 | $2.97M 10-Q · filed 2015-05-14 | $33.64M derived: sum of 2 quarters · filed 2016-03-15 | $30.03M derived: sum of 3 quarters · filed 2016-03-15 | |
| 2013-12-31 | $30.67M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $27.06M derived: sum of 2 quarters · filed 2016-03-15 | $25.58M 10-K · filed 2016-03-15 | |
| 2013-09-30 | -$3.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | -$5.09M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | -$1.48M 10-Q · filed 2014-08-14 | |||
| 2012-12-31 | $8.47M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |